Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00356798
Recruitment Status : Completed
First Posted : July 26, 2006
Last Update Posted : November 9, 2007
Ministry of Science and Technology of the People´s Republic of China
Information provided by:
Sinovac Biotech Co., Ltd

July 25, 2006
July 26, 2006
November 9, 2007
December 2005
Not Provided
To evaluate the safety of pandemic inactivated influenza vaccine by different does.
Same as current
Complete list of historical versions of study NCT00356798 on Archive Site
To evaluate the immunogenicity of pandemic inactivated influenza vaccine by different does.
Same as current
Not Provided
Not Provided
Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects
The Phase-I Clinical Trial Protocol for the Pandemic Inactivated Influenza Vaccine
Based on pre-clinical trial data and principle of GCP, the objective of phase I clinical trial is to evaluate safety and immunogenicity of Pan-flu vaccine, an inactivated whole virion H5N1 vaccine with aluminium hydroxide adjuvant.
Not Provided
Phase 1
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double
Primary Purpose: Prevention
Biological: an inactivated whole virion H5N1 vaccine, adjuvanted
Not Provided
Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z, Yang M, Sun R, Li C, Lin S, Ji M, Liu Y, Wang X, Wood J, Feng Z, Wang Y, Yin W. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet. 2006 Sep 16;368(9540):991-7.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
April 2006
Not Provided

Inclusion Criteria:

  • Males and females, age from 18 to 60 years old;
  • Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process;
  • Able and willing to complete the informed consent process.

Exclusion Criteria:

  • Woman who is breast-feeding or planning to become pregnant during the following 210 days of study participation;
  • Persons who engage in the following occupations: culturist, slaughter, sale and forwarder of avian;
  • Subject has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc;
  • Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain;
  • Autoimmune disease or immunodeficiency;
  • Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that requires the use of oral or intravenous corticosteroids;
  • Diabetes mellitus (type I or II), with the exception of gestational diabetes;
  • History of thyroidectomy or thyroid disease that required medication within the past 12 months;
  • Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years;
  • Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws;
  • Malignancy that is active or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of study;
  • Seizure disorder other than 1) febrile seizures under the age of two, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) a singular seizure not requiring treatment within the last 3 years;
  • Asplenia, functional asplenia or any condition resulting in the absence or removal o the spleen;
  • Guillain-Barre Syndrome (GBS);
  • Abnormal result of laboratory test as below:

    • Biochemistry assaying: Alanine Aminotransferase /Serum Glutamate Pyruvate Transaminase (ALT), Total Bilirubine Tbil (TBIL), Direct Bilirubine Tbil (DBIL), Blood Urea Nitrogen (BUN) and Creatinine (Cr).
    • Routine blood assaying, routine urine assaying.
    • HBsAg positive;
  • Pregnancy test positive for female;
  • Subject has received any of the following substances:

    • Immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis).
    • Blood products within 3 months prior to initial study vaccine administration.
    • Other study drug within 30 days prior to initial study vaccine administration. Live attenuated vaccines within 30 days prior to initial study vaccine administration.
    • Medically indicated subunit or killed vaccines, e.g. pneumococcal, or allergy treatment with antigen injections, within 14 days of study vaccine administration.
    • Current anti-TB prophylaxis or therapy.
  • Fever before vaccination, axillary temperature 37.0 centigrades.
  • Psychiatric condition that precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years; disorder requiring lithium; or suicidal ideation occurring within five years prior to enrollment.
  • Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent.
Sexes Eligible for Study: All
18 Years to 60 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Sinovac Biotech Co., Ltd
Ministry of Science and Technology of the People´s Republic of China
Principal Investigator: Jiangtao Lin, MD China-Japan Friendship Hospital
Sinovac Biotech Co., Ltd
November 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP